We found that antibodies capable of binding to IFN‐α subtypes and/or IFN‐β can be detected in up to 17% of hospitalized COVID‐19 patients and about one of five of these serum samples contained auto‐Abs that neutralized IFN‐I. This evidence concerns the gene DDX41 and COVID-19.